NASDAQ:TCRR

TCR2 Therapeutics (TCRR) Price Target & Analyst Ratings

$1.48

-0.09 (-5.73%)

(As of 06/1/2023)

Compare

Today's Range: $1.48
▼
$1.63
50-Day Range: $1.43
▼
$1.98
52-Week Range: $0.82
▼
$3.88

Volume: 3.91 million shs
Average Volume: 494,777 shs
Market Capitalization: $58.10 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.91

TCR2 Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 8 Analyst Ratings

Consensus Analyst Price Target

$4.91
232.05% Upside

High Prediction	$13.00
Average Prediction	$4.91
Low Prediction	$1.68

Type	Current 6/8/22 to 6/8/23	1 Month Ago 5/9/22 to 5/9/23	3 Months Ago 3/10/22 to 3/10/23	1 Year Ago 6/8/21 to 6/8/22
Consensus Rating	Hold	Hold	Hold	Moderate Buy
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	2 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	5 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	4 Hold rating(s)	3 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$4.91	$4.91	$6.20	$17.38
Predicted Upside	232.05% Upside	246.64% Upside	369.30% Upside	167.69% Upside

Get TCR2 Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for TCRR and its competitors with MarketBeat's FREE daily newsletter.

TCRR Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

TCRR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

TCR2 Therapeutics Stock vs. The Competition

Type	TCR2 Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.25	2.66	2.49
Consensus Rating	Hold	Buy	Hold
Predicted Upside	232.05% Upside	1,238.86% Upside	228.69% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Historical Target Prices and Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
3/24/2023	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$20.00 ➝ $1.72	+21.13%
3/23/2023	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral	$2.18 ➝ $1.68	+18.31%
3/23/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold	$2.00	+35.13%
3/9/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$18.00 ➝ $3.00	+93.55%
3/7/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$8.00 ➝ $3.00	+87.50%
3/7/2023	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
1/5/2023	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$8.00 ➝ $10.00	+817.42%
8/8/2022	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Butler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 6/8/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

TCRR Price Target - Frequently Asked Questions

What is TCR2 Therapeutics's consensus rating and price target?: According to the issued ratings of 8 analysts in the last year, the consensus rating for TCR2 Therapeutics stock is Hold based on the current 6 hold ratings and 2 buy ratings for TCRR. The average twelve-month price prediction for TCR2 Therapeutics is $4.91 with a high price target of $13.00 and a low price target of $1.68. Learn more on TCRR's analyst rating history.
Do Wall Street analysts like TCR2 Therapeutics more than its competitors?: Analysts like TCR2 Therapeutics less than other Medical companies. The consensus rating for TCR2 Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how TCRR compares to other companies.
Is TCR2 Therapeutics being downgraded by Wall Street analysts?: Over the previous 90 days, TCR2 Therapeutics's stock had 1 downgrade by analysts.

Does TCR2 Therapeutics's stock price have much upside?: According to analysts, TCR2 Therapeutics's stock has a predicted upside of 246.64% based on their 12-month price targets.
What analysts cover TCR2 Therapeutics?: TCR2 Therapeutics has been rated by EF Hutton Acquisition Co. I, Mizuho, and Wedbush in the past 90 days.

Stock Ratings Reports and Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

This page (NASDAQ:TCRR) was last updated on 6/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial